Stay updated on Switching to B/F/TAF in Virologically Suppressed Adults Clinical Trial
Sign up to get notified when there's something new on the Switching to B/F/TAF in Virologically Suppressed Adults Clinical Trial page.

Latest updates to the Switching to B/F/TAF in Virologically Suppressed Adults Clinical Trial page
- Check7 days agoChange DetectedThe page revision was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedThe page shows Revision: v3.5.0, replacing the previous v3.4.3. This appears to be a minor version update with no impact on study details or navigation.SummaryDifference0.0%

- Check50 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing the previous Revision: v3.4.2.SummaryDifference0.0%

- Check71 days agoChange DetectedAdded Revision: v3.4.2 and removed Revision: v3.4.1 in the revision notes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check79 days agoChange DetectedAdded a new publication citation (Andreatta et al., J Antimicrob Chemother, 2019) with revision 3.4.1, and removed the Erratum reference for the same article (revision 3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check86 days agoChange DetectedThe new screenshot shows the Study Details page with no additions or deletions to core content; the information on eligibility, endpoints, locations, and timeframes remains unchanged from the previous version. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Switching to B/F/TAF in Virologically Suppressed Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Switching to B/F/TAF in Virologically Suppressed Adults Clinical Trial page.